Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

American Journal of Pathology

Volumn 174, Issue 5, 2009, Pages 1597-1601

  Kuo, Kuan Ting ^a,b   Mao, Tsui Lien ^b   Jones, Siân ^a   Veras, Emanuela ^a   Ayhan, Ayse ^c   Wang, Tian Li ^a   Glas, Ruth ^d   Slamon, Dennis ^d   Velculescu, Victor E ^a   Kuman, Robert J ^a   Shih, Ie Ming ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Department of Palliative and Supportive Care Palliative Care Team and Seirei Hospice Seirei Mikatahara Hospital   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CATENIN; K RAS PROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; MESSENGER RNA; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CLEAR CELL CARCINOMA; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; SEQUENCE ANALYSIS; ADENOCARCINOMA; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; GENETICS; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MUTATION; OVARIAN NEOPLASMS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 65649128979     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081000     Document Type: Article

References (37)

1. Cho KR, Shih IM: Ovarian cancer. Annu Rev Pathol Mech Dis 2009, 4:287-313
2. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006, 94:1369-1374 (Pubitemid 43772268)
3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers Gynecol Oncol 2008, 109:370-376
4. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA: Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006, 102:285-291 (Pubitemid 44041640)
5. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller Jr AF: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996, 60:412-417 (Pubitemid 26077628)
6. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-2589 (Pubitemid 30331967)
7. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007, 105:404-408 (Pubitemid 46590333)
8. Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y: Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 2008, 18:937-942
9. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih Ie M: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006, 5:779-785
10. Salani R, Kurman RJ, Giuntoli R, 2nd, Gardner G, Bristow R, Wang TL, Shih IM: Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008, 18:487-491
11. Slamon DJ GW, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712 (Pubitemid 19147683)
12. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992, 89:9267-9271
13. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL: PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005, 25:322
14. Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM: Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 2007, 38:607-613 (Pubitemid 46399888)
15. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681 (Pubitemid 39446895)
16. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573 (Pubitemid 40799249)
17. Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004, 3:1221-1224 (Pubitemid 40268595)
18. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554 (Pubitemid 38541907)
19. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A: Targeting the PI3K p110a isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 2008, 14:6761-6769
20. Shih I-M, Kurman RJ: Ovarian tumorigenesis-a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518 (Pubitemid 38529752)
21. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IM, Wang TL: Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (in press)
22. Tan DS, Kaye S: Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007, 60:355-360 (Pubitemid 46596552)
23. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) - 4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008, 51:5522-5532
24. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, Garcia-Echeverria C, Maira SM: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008, 68:6598-6607
25. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863
26. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Bernhard EJ: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923
27. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug. SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008, 68:206-215
28. Marone R, Cmiljanovic V, Giese B, Wymann MP: Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008, 1784:159-185
29. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat R, Lin O, Soslow R, Venkatraman E, Boyd J: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gyncol Oncol 2003, 90:378-381 (Pubitemid 36952030)
30. Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS: p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001, 80:189-193 (Pubitemid 32158457)
31. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486
32. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE: p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993, 53:2128-2132 (Pubitemid 23145738)
33. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM: In ovarian neoplasms. BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004, 202:336-340
34. Obata K, Hoshiai H: Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest 2000, 50:39-43
35. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 2005, 18 Suppl 2:S19-S32 (Pubitemid 40188615)
36. Kurman RJ, Shih Ie M: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008, 27:151-160
37. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM: K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991, 139:777-785